NEW YORK (GenomeWeb News) — Stratagene today said third-quarter revenues decreased 2 percent as an unfavorable court decision caused net losses to balloon 817 percent.
Total receipts for the three months ended Sept. 30 decreased to $23.2 million from $23.7 million year over year. The company blamed part of the slide on declining sales in its gene-discovery and cloning systems products.
R&D spending remained flat at around $2.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.